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Cholesteryl ester transfer activity in patients with renal failure or renal
transplants. Plasma newly-synthesized cholesteryl ester transfer (NCET)
rate and concentrations of lipids, lipoproteins and apolipoproteins Al and
B were measured in chronic renal failure patients (dialysis independent
and dialysis dependent), patients with a functioning renal transplant and
in healthy control subjects with comparable ages and plasma triglycerides.
Plasma NCET rates and apoB concentrations were significantly higher in
patients treated by continuous ambulatory peritoneal dialysis (CAPD)
compared with controls. In normolipidemic subjects (cholesterol < 6.5
mmol/liter, triglycerides < 2.0 mmol/liter), plasma NCET rates did not
differ significantly from rates in the corresponding control subjects. In
hyperlipidemic subjects, plasma NCET rates were significantly higher than
rates in the normolipidemic subgroup. Plasma NCET rates were cone-
lated closely with plasma apoB levels in all renal patients combined (r =
0.754, N = 53, P < 0.001) and with plasma cholesteryl ester mass transfer(r = 0.853, N = 13, P < 0.001). We conclude that, in the absence of
hyperlipidemia, plasma NCET rate is normal in patients with chronic
renal failure irrespective of the treatment for uremia, and when hyperlip-
idemia is present NCET rates are raised and may contribute to elevated
levels of the proatherogenic apoB-containing lipoproteins.
Initial steps in the transport of cholesterol from peripheral
tissues to the liver (reverse cholesterol transport) include binding
of cell cholesterol by high density lipoproteins (HDL), esterifica-
tion of free cholesterol by lecithin:cholesterol acyltransferase
(LCAT) activity associated with HDL, and transfer of cholesteiyl
esters formed in HDL to triglyceride-rich lipoproteins [1, 2].
Cholesteryl ester transfer protein (CETP) catalyzes the redistri-
bution of newly synthesized cholesteryl esters from HDL to other
lipoproteins in plasma [3]. A substantial proportion of the cho-
lesteryl esters formed in the LCAT reaction are transferred to
triglyceride-rich lipoproteins and low density lipoproteins (LDL)
[4]. When hepatic LDL receptors are down-regulated, transfer of
cholestesyl esters into apoB-containing lipoproteins is thought to
result in accumulation of cholesteryl ester-enriched LDL particles
and very low density lipoprotein (VLDL) remnants in the circu-
lation, which can promote atherosclerosis [3]. On the other hand,
if hepatic clearance of apoB-containing lipoproteins is efficient
then transfer of cholesteryl esters to these lipoproteins, which are
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largely catabolised by the liver [5], may be an effective pathway for
removing excess cell cholesterol from the body. Thus, the quantity
of newly synthesized cholesteryl esters transferred into apoB-
containing lipoproteins could influence the rate of reverse cho-
lesterol transport. Efficient reverse cholesterol transport is be-
lieved to prevent accumulation of cholesterol in arterial tissue and
the development of atherosclerosis.
Patients with chronic renal failure [6] and renal transplant
recipients [7] have increased risk of coronary heart disease. In
patients treated by hemodialysis, there is evidence that reverse
cholesterol transport is deranged with abnormal transport of
cholesterol between cultured fibroblasts and plasma such that
cholesterol moves from plasma to cells [8]. Also, plasma choles-
terol esterification and transfer of cholesteryl esters from HDL
are greatly reduced [8, 9]. The low rate of cholesteryl ester
transfer in hemodialysis plasma is due to the low rate of cho-
lesteiyl esters synthesized by LCAT activity and the inefficient
transfer of these esters to apoB-containing lipoproteins of abnor-
mal composition [8]. In contrast, these defects are not present in
plasma from comparable patients treated by continuous ambula-
tory peritoneal dialysis (CAPD) [8]. Evidently the type of treat-
ment used to counteract uremia can influence intravascular
cholesterol metabolism. There is, however, little information
available on intraplasmatic cholesteryl ester transfer in dialysis
independent patients with chronic renal failure and renal trans-
plant recipients. Kidney transplantation, with a return to normal
renal function, corrects the deficiency in plasma LCAT activity
associated with uremia [10, 11]. However, immunosuppressive
drugs taken to maintain the grafts raise plasma lipid levels
[12—14], and hyperlipidemia accelerates plasma cholesteryl ester
transfer [15, 16]. On the other hand, corticosteroids, which are a
component of immunosuppressive therapy, normalize elevated
levels of plasma CETP in patients with nephrotic syndrome and
normal renal function [17]. Thus, the effect of treatments used in
renal failure on the transfer of newly synthesized cholesteryl esters
from HDL to apoB-containing lipoproteins warrants investiga-
tion. The aim of the present study was therefore to document
plasma newly synthesized cholesteryl ester transfer (NCET) rates
in both dialysis independent and dialysis dependent patients with
chronic renal failure and in renal transplant recipients, consider-
ing separately those with hyperlipidemia. Plasma NCET is deter-
mined by measuring the accumulation in apoB-containing li-
poproteins of cholesteryl esters generated from radiolabeled
plasma-free cholesterol, and is therefore an indicator of activity in
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the segment of reverse cholesterol transport involving LCAT and
CETP.
Methods
Subjects
Fifty-three patients with chronic renal failure or kidney grafts
(ages 15 to 77 years) were recruited from patients attending the
Otago Nephrology Unit. Patients with diabetic nephropathy, the
nephrotic syndrome or those receiving lipid-lowering therapy
were excluded. Thirteen patients were dialysis independent, 12
were receiving hemodialysis, 11 were treated by CAPD and 17
patients were renal transplant recipients. The etiology of renal
failure in the patients included glomerulonephritis (N = 32),
reflux nephropathy (N = 8), hypertension (N = 7), autosomal-
dominant polycystic kidney disease (N 2), and other causes
(N = 4). Eleven patients (1 dialysis independent, 8 CAPD and 2
hemodialysis) had evidence of ischemic heart disease. Ischemic
heart disease was diagnosed on the basis of clinical symptoms and
signs along with ECG and/or echocardiographic changes. Twenty-
two patients were receiving cardiovascular medications. Where
used, antihypertensive therapy was most commonly an angioten-
sin converting enzyme (ACE) inhibitor and/or dihydropyridine
calcium channel antagonist. Only one patient was taking a beta-
blocking drug. The majority of dialysis patients were taking
calcium carbonate as a phosphate binder and 1 alpha-calcitriol
supplementation. Two dialysis patients were receiving erythropoi-
etin subcutaneously. In the renal transplant recipients immuno-
suppression was with either azathioprine and prednisone (N = 5)
or triple therapy with cyclosporin A, azathioprine and prednisone(N = 12). One patient on hemodialysis was also receiving
azathioprine and prednisone for an underlying vasculitis. Patients
receiving dialysis were either on home hemodialysis or CAPD.
Hemodialysis patients were dialysing three times weekly (12—18
hr/week) using cellulose acetate hollow fiber dialyzers and acetate
dialysate. Patients on CAPD used the Baxter Disconnect system.
Dietaly protein intake was not restricted in any patient group.
Apart from advice to hemodialysis patients to restrict intake of
potassium-rich foods and fluid intake where necessary, dialysis
patients were not given any specific dietary advice. Six patients
were smokers (three on hemodialysis and three renal transplant
recipients).
Twenty-seven healthy subjects with ages and plasma lipid levels
comparable with those of the renal patients were recruited from
the population of Dunedin. None was taking any medication and
three smoked.
The study was approved by the Otago Area Health Board
Ethics Committee and participants gave written and informed
consent.
Methods
Blood was taken from subjects after an overnight fast and
immediately before the dialysis session in the case of patients
treated by hemodialysis. The blood was collected in tubes con-
taining disodium EDTA (1.5 mg/ml) and plasma was separated by
low-speed centrifugation at 4°C. VLDL were separated by ultra-
centrifuging plasma according to the Lipid Research Clinic's
protocol [18]. High density lipoprotein cholesterol (HDL-C) was
measured in the supernatant after precipitation of apoB-contain-
ing lipoproteins with dextran sulphate/magnesium chloride [19].
HDL3-C was measured in the supernatant after treating plasma
with polyethyleneglycol and pelleting the precipitate by centrifu-
gation [20]. Concentrations of low density lipoproteins cholesterol
(LDL-C) and HDL2-C were calculated by difference. The LDL-C
contains cholesterol from intermediate density lipoproteins
(IDL). Cholesterol, free cholesterol and triglycerides in plasma
and plasma fractions were measured using enzymatic kits and
calibrators from Boehringer Mannheim (Germany). Concentra-
tions of apoAl and apoB were determined by immunoturbidim-
etry [211 using materials from Boehringer Mannheim. Plasma
NCET was determined in duplicate by a radioisotope method
using endogenous plasma lipoproteins [22]. Briefly, an aliquot of
a [3F1] cholesterol-albumin emulsion was added to plasma and the
mixture was incubated at 4°C to equilibrate the radiolabelled
cholesterol with plasma free cholesterol. The mixture was then
incubated at 37°C for three hours. At the end of the incubation
period VLDL and LDL were precipitated by the addition of
phosphotungstate/magnesium chloride. The precipitate was ex-
tracted for lipids, the cholesteryl ester and free cholesterol
fractions were separated by thin layer chromatography and radio-
activity in the fractions was measured. Determination of plasma
free cholesterol concentration and total radioactivity added al-
lowed the expression of NCET in nmol/ml/hr. There is no
significant esterification of free cholesterol in the VLDL and LDL
fractions during the assay [22]. Aliquots of plasma for measure-
ment of NCET were stored briefly (approximately one month at
—80°C). Plasma CETP activity is reported as stable for several
months at —20°C [23]. Plasma cholesteryl ester mass transfer rates
were measured essentially as described previously [24] excepting
iodoacetate (1 mmol/liter) was used to inhibit plasma LCAT
activity [25]. The rate of cholesterol esterification in whole blood
was estimated by incubating aliquots of whole blood at 37°C and
4°C for 10 hours, determining plasma cholesteryl ester concentra-
tion (as the difference between total and free cholesterol mea-
surements) at the end of the incubation period and calculating the
increase in plasma cholesteryl ester content by subtracting mea-
surements at 4°C from those at 37°C. The presence of blood cells
does not influence plasma cholesterol esterification rates [26].
Plasma creatinine concentration was measured by routine auto-
mated methods in the laboratories of Dunedin Public Hospital.
Statistical analysis
Comparison of values among groups were made using analysis
of variances combined with Tukey's test. Pearson's product mo-
ment correlation coefficients were used to test for relationships
between variables and partial correlation analysis was used to
control for the influence of a third variable. Two-tailed tests of
significance were used and a P value of less than or equal to 0.05
was considered to be statistically significant.
Results
Characteristics of the patients with renal disease and the
control subjects are shown in Table 1. Apart from renal transplant
recipients who were younger, the ages were comparable for
patients in each treatment modality and with control subjects.
Rates of NCET (measured in triplicate) and cholesteryl ester
mass transfer (measured three times with quadruplicate choles-
terol and free cholesterol estimations) were compared in fresh
plasma from 11 healthy subjects and two patients regularly
receiving hemodialysis (cholesterol: 6.57 mmollliter and 4.87
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Table 1. Clinical characteristics of patients with renal disease and control subjects
Chronic renal failure
RT ControlsDI HD CAPD
N=13 N=12 N=11 N=17 N=27 P
Ageyears
Gender (M:F)
Body weight kg
BMI kg/rn
Creatinine .unolIliter
Duration of treatment
56 14
8:5
65.4 13.5
23.7 3.3
429 279°
60 51
45 13
7:5
74.0 13.0
24.6 3.7
769 352
48 32
65 7
9:2
74.4 8.1
26.4 3.1
680 231
13 10
38 14
9:8
68.9 13.2
24.0 3.1
139 79bcf
58 65
53 9
13:14
74.9 13.0
25.4 2.5
90 11
<0.001
NS
NS
<0.001
0.054
months
Values are mean SD.
Abbreviations are: DI, dialysis independent, HD hemodialysis: CAPD, continuous ambulatory peritoneal dialysis; RT, renal transplant recipients; NS,
not significant.
Significant differences by one-way analysis of variances: aversus controls; bHD versus RT; CDI versus HD; dRT versus CAPD; versus CAPD; 1RT
versus DI.
Table 2. Plasma newly synthesized cholesteryl ester transfer (NCET) rate and lipoprotein profile in patients with renal disease and control subjects
Chronic renal failure
RT ControlsDI HD CAPD
N=13 N=12 N=11 N=17 N=27 P
Plasma
NCET rate nmol/rnl/hr 25.5 10.5 24.4 10.5 32.4 12.5 27.9 10.4 22.1 7.9 0.05
TC rnmol/liter 6.06 1.68 6.17 1.56 7.43 1.46 6.62 1.36 6.34 0.78 NS
FC mmol/liter 1.42 0.43 1.53 0.47 1.58 0.53 1.58 0.44 1.54 0.21 NS
TG mmol/liter 1.69 0.63 2.07 1.13 2.19 0.94 1.72 0.81 1.77 0.77 NS
Apo Al g/liter
Apo B g/liter
1.26 0.29
0.97 0.31
1.34 0.17
0.95 0.32
1.25 0.14
1.33 0.34a
1.38 0.3
0.99 0.30
1.56 0.59
0.87 0.20
NS
<0.001
Lipoprotein lipids rnmol/liter
VLDL-TC 0.68 0.39 0.86 0.71 0.93 0.65 0.61 0.51 0.61 0.51 NS
VLDL-CE 0.42 0.23 0.48 0.37 0.57 0.40 0.34 0.28 0.38 0.32 NS
VLDL-FC 0.26 0.16 0.39 0.34 0.41 0.26 0.28 0.23 0.23 0.18 NS
VLDL-TG 1.01 0.51 1.40 1.01 1.27 0.74 1.09 0.70 0.91 0.59 NS
LDL-C 4.09 1.45 3.95 1.04 5.15 1.01 4.42 1.15 4.32 0.74 0.072
HDL-C 1.26 0.42 1.29 0.36 1.22 0.24 1.53 0.48 1.53 0.39 0.056
HDL2-C 0.54 0.30 0.53 0.24 0.51 0.23 0.63 0.36 0.73 0.31 NS
HDL3-C 0.72 0.22 0.75 0.18 0.71 0.13 0.90 0.18CC 0.80 0.12 0.015
Values are mean SD.
Abbreviations are: DI dialysis independent; HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis; RT, renal transplant recipients; NS,
not significant; NCET, newly synthesized cholesteryl ester transfer; TC, total cholesterol; FC, free cholesterol; TG, triglycerides; LDL-C, low density
lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.
Significant difference by one-way analysis of variances are: aversus controls; bCAPD versus HD; CCAPD versus RT; dCAPD versus DI; RT versus
DI.
mmol/liter; triglycerides: 1.46 mmol/liter and 2.27 mmol/liter,
respectively). Plasma NCET was correlated significantly (r =
0.853, N = 13, P < 0.001) with plasma cholesteryl ester mass
transfer. Plasma NCET (21.1 1.8 nmol/ml/hr, N = 13, mean
SD) and plasma cholesteryl ester mass transfer (22.3 1.9
nmol/ml/hr, N = 13, mean SD) were not significantly different in
the subjects. In the two hemodialysis patients, plasma NCET rates
were 24.3 nmol/ml/hr and 15.5 nmol/ml/hr and the corresponding
plasma cholesteryl ester mass transfer rates were respectively 21.2
nmol/ml/hr and 16.5 nmol/ml/hr. Plasma LCAT activities mea-
sured in triplicate by the method of Channon and coworkers [22]
in these two patients were 55.8 nmol/ml/hr and 51.1 nmol/ml/hr,
respectively. Plasma NCET rate assayed in pentuplicate in a fresh
normolipidemic plasma sample (26.1 2.9 nmol/mI/hr, mean
SD) and in three hypertriglyceridemic plasmas (73.5 13.2
nmol/ml/hr, mean SD of 3 pentuplicate measurements) was not
significantly different compared with rates in an aliquot of plasma
which had been stored at —80°C for one week (normolipidemic
plasma: 26.2 1.8 nmollmllhr, mean s; hypertriglyceridemic
plasmas: 73.2 14.8 nmol/ml/hr, mean SD of three pentuplicate
measurements).
The data in Table 2 show that plasma NCET rates and apoB
concentrations were significantly higher in CAPD patients com-
pared with control values. ApoB levels in these patients were also
significantly higher than values in renal patients receiving other
treatments. Plasma HDL3-C concentration was significantly
higher in renal transplant recipients compared with levels in
dialysis independent patients with chronic renal failure or those
treated by CAPD.
Cholesterol esterification rates in whole blood were not signif-
icantly different in renal transplant recipients (56 17 nmol/ml/
hr, N = 17), patients treated by hemodialysis (42 15 nmol/ml/hr,N = 12) or CAPD (44 22 nmol/ml/hr, N 11) and dialysis
independent patients with chronic renal failure (41 26 nmol!
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Table 3. Plasma newly synthesized cholesteryl ester transfer (NCET) rate in normolipidemic and hyperlipidemic patients with renal disease and
control subjects
Plasma NCET rate nmol/ml/hr
PChronic renal failure
RT ControlsDl HD CAPD Treatment Lipids
Normolipidemic(TC < 6.5 mmol/liter
TG <2 mmol/liter)
Hyperlipidemic(TC  6.5 mmol/liter
TG  2 mmol/liter)
20.7 2.7
N = 4
27.6 9,7
N = 9
19,5 4.2
N = 6
29.2 13.0
N = 6
22.0 3.6
N = 3
36.3 12.5
N = 8
22.9 6.2
N = 8
32.4 11.7
N = 9
18.0 5.6
N = 15
27.3 7.6
N = 12
NS
NS
0.003
0.003
Values are mean SD, Significance is obtained from one-way analysis of variances (treatment) or two-factor analysis of variances (normolipidemic
versus hyperlipidemic groups). Abbreviations are: NCET, newly synthesized cholesterol ester transfer; Dl, dialysis independent; lID, hemodialysis;
CAPD, continuous ambulatory peritoneal dialysis; RT, renal transplant; TC, total cholesterol; TG, triglycerides; NS, not significant.
IHD[+]N=11 IHD[—]N=42 P
NCET rate nmol/ml/hr 26.0 5.4 27.8 11.6 NS
Age years
BMI kg/rn2
65 7
25.2 3.0
45 16
24.4 3.3
<0.001
NS
Duration of treatment months 15 14 53 51 <0.001
Creatinine pinol/liter 580 204 435 374 NS
TC mmol/liter 6.98 0.98 6.43 1.66 NS
VLDL-C mrnol/liter 0.62 0.37 0.79 0.61 NS
LDL-C mrnol/liter 4.93 0,83 4.24 1.28 <0.05
HDL-C mmol/liter 1.33 0.36 1.34 0.43 NS
HDL2-C inmol/liter 0.57 0.35 0.56 0.28 NS
HDL3 mmol/liter 0.77 0.14 0.79 0.20 NS
TG mrnol/liter 1.72 0.62 1.93 0.94 NS
VLDL-TG mmol/liter 0.94 0.48 1.24 0.79 NS
ApoAl g/liter 1.27 0.18 1.33 0.26 NS
ApoB glliter 1.17 0.23 1.01 0.36 NS
ml/hr, N = 13) compared with rates in a separate group of healthy
subjects (55 15 nmol/ml/hr, N = 8). These rates were signifi-
cantly (P < 0.05) lower in hemodialysis patients compared with
renal transplant recipients. Cholesteiyl ester accumulation in
incubated blood was determined as part of a separate study.
Table 3 shows plasma NCET rates in subjects divided arbitrarily
into normolipidemic (cholesterol < 6.5 mmol/liter and triglycer-
ides < 2.0 mmol/liter) and hyperlipidemic (cholesterol  6.5
nimol/liter or triglycerides  2.0 mmol/liter) subgroups. Plasma
NCET rates were not significantly different by treatment in the
normolipidemic subgroup or the hyperlipidemic subgroup. Rates
of plasma NCET were significantly higher in hyperlipidemic
subjects compared with normolipidemic subjects.
Renal transplant recipients treated with azathioprine and pred-
nisone had plasma NCET rates (29.8 12.3 nmol/ml/hr, N = 5,
mean SD) which were not significantly different from rates in
corresponding patients treated with azathioprine, prednisone and
cyclosporin A (27.1 10.1 nmol/ml/hr, N = 12, mean SD).
Patients with both renal disease and ischemic heart disease were
I...
Ij
apoB, g/llter
Fig. 1. Correlation between plasma newly synthesised cholesteiyl ester trans-
fer (NCET) rate and plasma apoB concentration in patients with chronic
renal failure or renal transplants. Symbols are: (•) hemodialysis (N = 12,
r = 0.760, P < 0.01); (0) CAPD (N = 11, r = 0.915, P < 0.001); () renal
transplant recipients (N = 17, r = 0.653, P < 0.01); (0) dialysis
independent patients with chronic renal failure (N = 13, r = 0.662,P <
0.05). r 0.754; P < 0.001.
older with higher levels of LDL-C and similar rates of plasma
NCET compared to those with no evidence of ischemic heart
disease (Table 4).
Correlational analyses
Plasma NCET rate was correlated significantly (r = 0.754, N =
53, P < 0.001) with plasma apoB concentration in all renal
patients combined (Fig. 1) and control subjects (r = 0.477, N =
27, P < 0.05). Also plasma NCET was correlated significantly with
plasma cholesterol (r 0.692, N = 53,P < 0.001) and triglyceride(r = 0.664, N = 53, P < 0.001) concentrations but not with age (r
0.087) and BMI (r = 0.116). When plasma cholesterol concen-
tration was held constant in partial correlation analysis, the
correlation between plasma apob concentration and NCET rate
in renal patients remained significant (r = 0.415, N = 53, P =
0.001). Similarly plasma NCET rate was correlated significantly
with plasma apoB concentration when plasma triglyceride levels
were held constant (r 0.616, P < 0.001).
Table 4. Plasma newly synthesized cholesteryl ester transfer (NCET)
rate, clinical characteristics and plasma lipid, lipoprotein and
apolipoprotein concentrations in patients with renal disease with
ischemic heart disease (IHD[+]) and those with no evidence of
ischemic heart disease (IHD [—])
60
50
40
e •
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U
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U
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Values are mean SD. Abbreviations are: BMI: body mass index; TC,
total cholesterol; VLDL-C, very low density lipoprotein cholesterol; LDL,
low density lipoprotein; HDL, high density lipoprotein; TG, triglycerides;
VLDL-TG, very low density lipoprotein triglycerides.
1.0 1.5 2.0
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Discussion
Our data show that hyperlipidemia is associated with raised
plasma NCET rates in patients with renal disease and is essen-
tially normal in normolipidemic patients irrespective of the treat-
ment used to control uremia. Also plasma NCET rate was closely
associated with plasma apoB concentration and high transfer rates
of newly synthesised cholesteryl esters from HDL to apoB-
containing lipoproteins may be linked with the hyperapobetali-
poproteinemia of CAPD patients.
In vivo cholesteryl ester transfer is influenced by several factors
including composition and levels of plasma lipoproteins, CETP
concentration and transfer protein inhibitor levels. The plasma
NCET assay used in the present study incorporates several of
these factors and is a measure of cholesteryl ester flux between
HDL and apoB-containing lipoproteins in the presence of native
lipoproteins and LCAT activity. Moreover, our data show that
plasma NCET rates are similar to rates of plasma cholesteryl ester
mass transfer and values in healthy subjects were comparable with
rates reported in previous studies [15, 22, 24, 27—31].
Plasma NCET rates depend on plasma LCAT activity and
cholesteryl ester mass transfer. Thus low rates of plasma NCET
would be expected in normolipidemic hemodialysis patients and
undialyzed patients with chronic renal failure as judged by previ-
ous reports of low cholesteryl ester mass transfer rates and LCAT
activity in the former [8] and low LCAT activity in the latter [32].
However, in the present study, plasma NCET rates in these
categories of renal patients were similar to values in the healthy
controls. Normal NCET rates could theoretically result from
reduced plasma LCAT activity coupled with a counterbalancing
increase in cholesteiyl ester mass transfer. The tendency toward
lower cholesteryl ester accumulation in incubated whole blood
suggests that plasma LCAT rates in the undialyzed and hemodia-
lyzed patients with renal failure might be lower than normal but
not as low as the approximately one-third normal rates in hemo-
dialysis patients reported by Dieplinger, Schoenfeld and Fielding
[8]. On the other hand, plasma LCAT activity was not abnormally
low and the rate of cholesteryl ester mass transfer did not appear
to be abnormally high and was similar to NCET rates in two
virtually normolipidemic hemodialysis patients we studied. Fur-
thermore, normal plasma LCAT activity has been reported in
patients treated by hemodialysis [32], indicating that low LCAT
activity is not a consistent feature in these patients. It is possible
that plasma LCAT activity was not sufficiently low to appreciably
reduce plasma NCET rates in undialyzed or hemodialyzed pa-
tients with chronic renal failure.
The reason for the apparent discrepancy between the present
findings of normal NCET rates and reported data indicating low
cholesteryl ester transfer in hemodialysis patients [8] is not
entirely clear. The patients in the previous study were consider-
ably lighter [8] and were probably on a restricted diet. It is
possible that low nutrient intake and specifically low cholesterol
intake reduces plasma CETP concentration and cholesteryl ester
transfer. Changes in dietary cholesterol are linked with changes in
plasma CETP and CETP mRNA levels in humans [33]. Also,
dietary intake influences plasma cholesterol levels which are
associated with plasma CETP concentration [341. Thus low
plasma cholesterol levels (mean, 3.42 mmol/liter) in the hemodi-
alysis patients studied by Dieplinger and coworkers [8] are in
accord with low nutrient intake and reduced levels of plasma
CETP and cholesteryl ester transfer. The low plasma LCAT
activity in these patients [8} may also be due to low nutrient intake
since a recent study has shown that a low-calorie diet reduces
cholesterol esterification in plasma [35]. The markedly higher
body weight in the current hemodialysis patients is undoubtedly
due to higher nutrient intake which is consistent with higher levels
of plasma cholesterol, CETP, cholesteryl ester transfer and finally
NCET.
Plasma cholesteryl ester transfer and LCAT activity are re-
ported as essentially normal in normolipidemic CAPD patients
[8]. Our data are in line with these findings and showed normal
rates of plasma NCET in the small number of CAPD patients with
plasma lipids in the arbitrarily defined normal range. The elevated
plasma NCET in the total group of CAPD patients was therefore
due to the presence of hyperlipidemic individuals. Ai increase in
plasma NCET with hyperlipidemia is consistent with raised
plasma cholesteryl ester mass transfer documented previously in
hyperlipidemic subjects [15, 16].
In renal transplant recipients accelerated plasma NCET rates
were associated with hyperlipidemia which was probably due at
least in part to the immunosuppressive therapy these patients
were receiving. Increases in all lipoprotein fractions have been
reported at some stage during prednisone treatment [36, 37] and
cyclosporin A raises plasma LDL levels [12]. Corticosteroid
therapy is also associated with a reduction in plasma CETP in
both normal subjects and in patients with nephrotic syndrome [17]
and with reduced liver CETP mRNA and plasma CETP in CETP
transgenic mice [3]. However, in spite of the fact that all the renal
transplant recipients in the present study were treated with
prednisone, plasma NCET rates tended to be slightly higher in
normolipidemic transplant patients compared with controls. We
cannot rule out the possibility that azathioprine, a component of
immunosuppressive therapy, raises plasma NCET rates which are
then normalized by concurrent corticosteroid therapy. It seems
unlikely that treatment with cyclosporin A influences plasma
NCET rates which were comparable in patients treated with triple
therapy or azathioprine and prednisone. Another possibility is
that plasma CETP concentrations may not be rate-limiting for
cholesteryl ester transfer in patients with kidney grafts. Overall it
appears that plasma NCET rates are not abnormal during immu-
nosuppressive therapy unless hyperlipidemia develops.
A major finding of the present study was the close association
between plasma NCET rates and apoB concentrations in renal
patients. The mechanism underlying this correlation is uncertain
and may involve a direct effect of CETP on apoB levels and/or an
effect of varying levels of apoB-containing lipoproteins on plasma
NCET. A previous study has reported a correlation between
plasma CETP concentrations and apoB levels in patients with
nephrotic syndrome [17]. Thus it is conceivable that apoB levels
are related to CETP concentrations and subsequently to NCET
rates in the present renal patients. CETP might directly increase
apoB levels by altering the formation and/or catabolism of LDL
[38]. Furthermore evidence for a direct effect of CETP on plasma
apoB levels has been recently obtained from studies using trans-
genic mice which showed an increase in plasma apoB levels when
primate CETP was expressed [39]. Plasma levels of apoB-contain-
ing lipoproteins and particularly triglyceride-rich particles are
acceptors of cholestetyl esters transferred from HDL, and are
therefore an important determinant of plasma cholesteryl ester
mass transfer [15] and NCET rates which were closely correlated
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with plasma triglycerides in our data. However, the correlation
between plasma NCET rate and apoB concentration was inde-
pendent of plasma triglyceride levels, suggesting that the capacity
of apoB-containing lipoproteins for accepting cholesteryl esters
may not be the major factor underlying the correlation.
Hyperapobetalipoproteinemia has been previously identified in
patients treated by CAPD [40], but the factors responsible for this
abnormality are not clear. The elevated levels of plasma apoB in
the present CAPD patients are consistent with the presence of
hyperapobetalipoproteinemia. In addition plasma NCET rates
were raised which coupled with the correlation between plasma
NCET rate and apoB concentration suggest that accelerated
cholesteryl ester transfer may be linked with hyperapobetali-
poproteinemia in patients treated by CAPD.
Elevated plasma apoB levels have been associated with CHD in
several studies [41—43], and raised plasma NCET rates have also
been reported in patients with angiographic evidence of coronary
artery disease [27]. However, in the present study, plasma apoB
concentrations and NCET rates were not predictors of overt
ischemic heart disease (IHD) in renal patients. Instead, estab-
lished risk factors including older age and higher LDL-C levels
distinguished the affected individuals. Nevertheless, plasma
NCET rates in renal patients were similar to levels reported
previously in patients with angiographic evidence of IHD (27.8
12.2 nmol/ml/hr) [27], possibly reflecting the increased risk of
IHD in patients with end-stage renal disease. These findings
require testing in a larger sample of renal patients.
There are limitations to the present study. The study was cross
sectional and does not take into account pretreatment levels of
measured variables. Also the comparatively small number of renal
patients in each category increases the risk of a non-representa-
tive sample. A heterogenous group of patients was deliberately
chosen to reflect the current clinical pattern seen in renal failure
rather than preselecting for different risk factors. The exception
being the exclusion of diabetic nephropathy or the nephrotic
syndrome with well-documented lipid abnormalities which would
have further complicated the results. The patients with renal
disease were taking a variety of medications. While most of the
drugs prescribed were not known to affect lipid metabolism (apart
from those taken by renal transplant patients), an effect of those
agents on plasma NCET rate has not been positively excluded.
Finally, dietary intake was not controlled and may influence
plasma NCET rates and lipids, lipoproteins and apolipoprotein
concentrations.
In conclusion, this study shows that plasma NCET rate is closely
associated with plasma apoB and lipid levels in patients with renal
disease and is elevated similarly with hyperlipidemia in both renal
patients and subjects without renal disease. The data also suggest
that raised plasma NCET rates may not be the inevitable conse-
quence of renal disease and its treatment because transfer activity
is normal when hyperlipidemia is absent. Whether or not reduc-
tion of plasma lipids by drug treatment and diet also reduces
NCET rates in hyperlipidemic patients with renal disease warrants
further study.
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